Navigation Links
The Deal Names Abbott Top Dealmaker for Third Consecutive Year
Date:9/20/2010

The Deal Names Abbott Top Dealmaker for Third Consecutive Year -- ABBOTT PARK, Ill., Sept. 20 /PRNewswire-FirstCall/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Magazines, Publishing & Information Services, Biotechnology, Health Care & Hospitals, Medical Pharmaceuticals, Pharmaceuticals, Awards Click to view news release full screen  

The Deal Names Abbott Top Dealmaker for Third Consecutive Year

   

Awards Recognize Industry-Leading Companies That Demonstrate Effective Strategic Use of Mergers and Acquisitions Over Past Three Years

ABBOTT PARK, Ill., Sept. 20 /PRNewswire-FirstCall/ -- The Deal magazine has named Abbott (NYSE: ABT) as one of its Most Admired Corporate Dealmakers for the third consecutive year.  The Deal honored Abbott as its Most Admired Dealmaker in pharma/biotech for the most effective and consistent use of acquisitions and divestitures since January 2007.  

Over the past 24 months, Abbott has successfully executed on a number of strategic acquisitions that have enhanced the company's diversity, geographic reach and pipeline, and positioned the company for leadership in new, fast-growing markets.  Recently, the company completed its acquisition of Piramal Healthcare Solutions, bringing immediate market leadership in India, the world's second-fastest growing pharmaceutical market.  

"Abbott is honored to again be recognized by The Deal for our track record of acquisitions," said Miles D. White, chairman and chief executive officer, Abbott.  "In 2010, Abbott has successfully executed on a series of transactions to establish a leading presence in emerging markets, enhance its pharmaceutical pipeline and capitalize on global growth opportunities to drive continued top-tier performance."

In 2010, Abbott has:

  • Acquired Solvay Pharmaceuticals, complementing and diversifying its pharmaceutical portfolio and expanding Abbott's presence in key global emerging markets.
  • Purchased Facet Biotech, adding innovative oncology and neuroscience compounds to existing research expertise.
  • Announced a licensing agreement with Zydus Cadila to promote a portfolio of pharmaceutical products in 15 high-growth emerging markets.
  • Acquired a novel investigational biologic compound to treat chronic pain, enhancing Abbott's early-stage pharmaceutical pipeline.
  • Announced a collaboration with Neurocrine and Pierre Fabre to develop and commercialize treatments for endometriosis and oncology, respectively.

  • The Deal's readers rated Abbott best on the award criteria: choice of targets and strategy; price paid (or received) compared to value; execution, including integration; and overall quality of the deal team.  Companies considered for the survey have a market capitalization of $5 billion or more as of Dec. 31, 2009, closed the highest number and value of transactions and generated the largest increase in market capitalization over a three-year period ended Dec. 31, 2009.  

    About The Deal LLCThe Deal LLC (www.TheDeal.com) is a diversified media and information company. We report, analyze and disseminate business and financial news and data that offer fresh insights on the deal economy, a set of interrelated activities, focused on dealmaking of all kinds, whose purpose is to generate corporate and capital growth in a continually changing global market. We serve the global deal community – corporate and financial dealmakers, advisers and institutional investors – with The Deal Pipeline, a transaction information service, and The Deal magazine, a business and financial magazine, website and event brand. The Deal LLC, a privately held company, is owned by private investment funds sponsored by Wasserstein & Co. LP.  

    About AbbottAbbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics.  The company employs nearly 90,000 people and markets its products in more than 130 countries.  

    Abbott's news releases and other information are available on the company's Web site at www.abbott.com.


    '/>"/>

    SOURCE Abbott
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Intarcia Therapeutics Names Kurt Graves Executive Chairman to Advance Strategic Interests and Broaden Commercial Goals
    2. FierceBiotech Names VentiRx Pharmaceuticals as One of the Fierce 15 Biotech Companies of 2010
    3. Windhover Information Names D-Tagatose One of Top 10 Most Promising CV/Metabolic Drugs in Development
    4. FierceBiotech Names Obesity Company Gelesis to Fierce 15 List of Top Emerging Biotech Companies
    5. AAIPharma Services Corp. Names Patrick Walsh Chief Executive Officer
    6. INC. 5000 Names ClinixMIS for Third Time
    7. SL Industries Names Louis J. Belardi Chief Financial Officer
    8. BayCare Health System Names Tim Thompson Chief Information Officer
    9. Watson Names Sigurdur Oli Olafsson Executive Vice President, Global Generics
    10. K-V Pharmaceutical Names Thomas McHugh Chief Financial Officer
    11. Ikaria® Names New Chief Financial Officer
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:4/20/2017)... , April 20, 2017 Research and ... Pharmaceutical Contract Manufacturing Services Market Analysis By Service (Manufacturing, Research), ... Forecasts, 2014 - 2025" report to their offering. ... The Latin American pharmaceutical ... billion by 2025 Low drug registration cost in ...
    (Date:4/19/2017)... The Mobile X-Ray product segment is the most ... the forecast period Mobile X-Ray segment is the ... X-Ray devices market, which is estimated to be valued at ... CAGR of 7% over the forecast period. Mobile X-Ray segment ... US$ 100 Mn in 2017 over 2016. The segment,s revenue ...
    (Date:4/19/2017)... Global Prostate Cancer Therapeutics Market: Overview ... cancer therapeutics market analyzes the current and future ... prostate cancer, launch of promising emerging therapies, as ... drugs & therapeutic biological products, and high growth ... side effects are some of the drivers expected ...
    Breaking Medicine Technology:
    (Date:4/28/2017)... ... April 28, 2017 , ... Datta ... M.D. has joined the revolutionary endoscopic practice under Dr. Datta. Patel is a ... Pain Medicine. The patented, revolutionary eDiscSculpt Technique created and used by Datta Endoscopic ...
    (Date:4/28/2017)... ... April 28, 2017 , ... People are starting to ... “Wearing a hearing aid doesn’t have the stigma it had when great-grandpa wore his ... of Greater Boston, in a NALA North American Speaker Series (NASS) segment. ...
    (Date:4/28/2017)... ... April 28, 2017 , ... ... the Brooke Grove Foundation implement a Microsoft Dynamics GP solution that integrates to ... ERP expert that specializes in long-term care, Brooke Grove now has the capability ...
    (Date:4/28/2017)... ... 2017 , ... Christie Medical Holdings, Inc. , with its market-leading ... Medical Inc. , a leader in infusion therapy and pain management. , Intravenous ... percent of hospital patients receiving a peripheral IV catheter as part of their treatment ...
    (Date:4/27/2017)... ... April 27, 2017 , ... The American Brain Foundation ... Leadership in Neurology Award (PLINA). The couple joins a prestigious list of past ... Walter Mondale, actor Michael J. Fox and former U.S. Attorney General Janet Reno. ...
    Breaking Medicine News(10 mins):